CD21/CR2 (2G9) Mouse mAb recognizes endogenous levels of CD21/CR2 protein.

Monoclonal antibody is produced by immunizing animals with a prokaryotic recombinant protein corresponding to the external domain of human CD21/CR2 protein.

Complement receptor type 2 (CD21/CR2) is a type 1 transmembrane glycoprotein whose expression is largely restricted to B lymphocytes and follicular dendritic cells (1,2). Research studies have shown that CD21/CR2 functions to bind the complement fragments iC3b, C3dg, and C3d, which function to activate the alternative complement pathway and MAC formation (3,4). In addition to its function as a complement receptor, CD21/CR2 also functions as the B lymphocyte receptor for Epstein-Barr virus (5) and interferon alpha (6). Research studies have also shown that CD21/CR2 participates in B cell activation, proliferation, and protection from apoptosis through its association with components of the B cell coreceptor signaling complex such as CD19 and CD21 (7-9).